Evidence map›Paper›PMID 37207126›Full record

ReviewFrontiers in bioengineering and biotechnology2023

Venom biotechnology: casting light on nature's deadliest weapons using synthetic biology.

Tim Lüddecke, Anne Paas, Richard J Harris, Lea Talmann, Kim N Kirchhoff, André Billion, Kornelia Hardes, Antje Steinbrink, Doreen Gerlach, Bryan G Fry and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Therapeutic Promise and Biotechnological Prospects ofInternational journal of molecular sciences · 2025
    Review
  8. Article
  9. Review
  10. Prospects and challenges of recombinant spider venom enzymes: insights fromFrontiers in bioengineering and biotechnology · 2025
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Tim LüddeckeDepartment of Bioresources, Fraunhofer Institute for Molecular Biology and Applied Ecology, Giessen, Germany.
Anne PaasDepartment of Bioresources, Fraunhofer Institute for Molecular Biology and Applied Ecology, Giessen, Germany.
Richard J HarrisVenom Evolution Lab, School of Biological Sciences, The University of Queensland, Brisbane, QLD, Australia.
Lea TalmannSyngenta Crop Protection, Stein, Switzerland.
Kim N KirchhoffDepartment of Bioresources, Fraunhofer Institute for Molecular Biology and Applied Ecology, Giessen, Germany.
André BillionDepartment of Bioresources, Fraunhofer Institute for Molecular Biology and Applied Ecology, Giessen, Germany.
Kornelia HardesDepartment of Bioresources, Fraunhofer Institute for Molecular Biology and Applied Ecology, Giessen, Germany.
Antje SteinbrinkLOEWE Centre for Translational Biodiversity Genomics (LOEWE-TBG), Frankfurt am Main, Germany.
Doreen GerlachDepartment of Bioresources, Fraunhofer Institute for Molecular Biology and Applied Ecology, Giessen, Germany.
Bryan G FryVenom Evolution Lab, School of Biological Sciences, The University of Queensland, Brisbane, QLD, Australia.
Andreas VilcinskasDepartment of Bioresources, Fraunhofer Institute for Molecular Biology and Applied Ecology, Giessen, Germany.
Fraunhofer Institute for Molecular Biology and Applied Ecology · DELOEWE Centre for Translational Biodiversity Genomics · DEUniversity of Queensland · AUSyngenta (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Venoms are complex chemical arsenals that have evolved independently many times in the animal kingdom. Venoms have attracted the interest of researchers because they are an important innovation that has contributed greatly to the evolutionary success of many animals, and their medical relevance offers significant potential for drug discovery. During the last decade, venom research has been revolutionized by the application of systems biology, giving rise to a novel field known as venomics. More recently, biotechnology has also made an increasing impact in this field. Its methods provide the means to disentangle and study venom systems across all levels of biological organization and, given their tremendous impact on the life sciences, these pivotal tools greatly facilitate the coherent understanding of venom system organization, development, biochemistry, and therapeutic activity. Even so, we lack a comprehensive overview of major advances achieved by applying biotechnology to venom systems. This review therefore considers the methods, insights, and potential future developments of biotechnological applications in the field of venom research. We follow the levels of biological organization and structure, starting with the methods used to study the genomic blueprint and genetic machinery of venoms, followed gene products and their functional phenotypes. We argue that biotechnology can answer some of the most urgent questions in venom research, particularly when multiple approaches are combined together, and with other venomics technologies.

Indexed as

biodiscoverybiosensorsCRISPRfunctional genomicsheterologous expressionorganoidsRNAisynthetic biology

Identifiers

PMID37207126
PMCPMC10188951
OpenAlexW4368405171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.